Page 1 | Search Results | Blood | American Society of Hematology

1-19 of 19

Sort by

Sort Order Select

Journal Articles

Rituximab Dose Adjusted EPOCH Improves Progression-Free Survival of Patients Affected By Diffuse Large Cell Lymphomas with Double Expression of MYC and BCL2 Proteins

Anna Dodero, MD, Anna Guidetti, MD, Alessandra Tucci, MD, Alessio Pellegrinelli, Antonello Cabras, MD, Liliana Franca Devizzi, MD, Lucia Farina, Luca Pappalettera, MD, Alberto Mussetti, MD, Maria Chiara Di Chio, MD, Rosa Jessica, MD, Martina Soldarini, MD, Angela Passi, MD, Paola Matteucci, MD, Stefano A. Pileri, Giuseppe Rossi, MD, Paolo Corradini, MD

Blood (2017) 130 (Supplement 1): 2844.

https://doi.org/10.1182/blood.V130.Suppl_1.2844.2844

Published: 2017

Journal Articles

TARC before ASCT Is Highly Predictive of Outcome in Patients with Relapsed or Refractory (R/R) Classical Hodgkin Lymphoma (cHL) after First-Line Therapy

Simonetta Viviani, MD, Francesco Spina, MD, Arabella Mazzocchi, Maria Galbiati, Flavio Crippa, MD, Lucia Farina, MD PhD, Anna Guidetti, MD, Massimo Di Nicola, Liliana Franca Devizzi, MD, Paola Matteucci, MD, Michele Magni, MD, Anna Dodero, Alessandro M. Gianni, MD, Paolo Corradini, MD

Blood (2016) 128 (22): 3009.

https://doi.org/10.1182/blood.V128.22.3009.3009

Published: 2016

Journal Articles

Brentuximab Vedotin (BV) an Effective Treatment for Autologous (ASCT) and/or Allogeneic (alloSCT) Transplant naïve Patients with Relapsed/Refractory (R/R) Hodgkin Lymphoma (HL) : A retrospective Single-Institution Study

Simonetta Viviani, MD, Serena Dalto, MD, Paola Matteucci, MD, Massimo Di Nicola, MD, Anna Guidetti, MD, Liliana Devizzi, MD, Michele Magni, MD, Anna Dodero, MD, Lucia Farina, MD, Francesco Spina, MD, Alessandro M. Gianni, MD, Paolo Corradini, MD

Blood (2014) 124 (21): 5428.

https://doi.org/10.1182/blood.V124.21.5428.5428

Published: 2014

Journal Articles

High Cure Rates of the Short-Term GITIL Chemotherapy Programme for Adult Patients with Burkitt Lymphoma

Jacopo Mariotti, MD, Anna Guidetti, MD, Michele Magni, MD, Paola Matteucci, MD, Liliana Devizzi, MD, Andrés J.M. Ferreri, Paolo Corradini, MD, Anna Dodero, MD, Amalia De Renzo, Alessandro Massimo Gianni, MD, Massimo Di Nicola, MD

Blood (2014) 124 (21): 1734.

https://doi.org/10.1182/blood.V124.21.1734.1734

Published: 2014

Journal Articles

Rituximab Followed by Involved Fields Radiotherapy (IF-RT) in Stage I-II Follicular Lymphoma (FL): Long Term Results,

Marco Ruella, MD, Andrea Filippi, MD, Anna DI Russo, MD, Daniele Caracciolo, MD, Paola Matteucci, MD, Michele Magni, MD, Massimo Di Nicola, MD, Umberto Ricardi, MD, Vittorio Montefusco, MD, Guido Parvis, MD, Corrado Tarella, MD, Alessandro M. Gianni, MD, Liliana Devizzi, MD

Blood (2011) 118 (21): 3699.

https://doi.org/10.1182/blood.V118.21.3699.3699

Published: 2011

Journal Articles

Safety, Tolerability and Activity of Ofatumumab, Bendamustine and Dexamethasone Combination As First-Line Treatment of Mantle-Cell Lymphoma in the Elderly: A Multicenter Study

Blood (2011) 118 (21): 1647.

https://doi.org/10.1182/blood.V118.21.1647.1647

Published: 2011

Journal Articles

The Risk of Secondary Myelodysplastic Syndrome/Acute Leukemia Following High-Dose Yttrium-90 Ibritumomab Tiuxetan Is Analogous to That Observed Following High-Dose Chemotherapy: a Matched-Pair Analysis In Non-Hodgkin Lymphoma Patients.

Anna Guidetti, MD, Carmelo Carlo-Stella, MD, Marco Ruella, MD, Rosalba Miceli, MD, Liliana Devizzi, MD, Daniela Sia, PhD, Silvia Locatelli, PhD, Arianna Giacomini, PhD, Michele Magni, MD, Paola Matteucci, MD, Stefano Buttiglieri, PhD, Alessandra Risso, PhD, Luigi Mariani, MD, Roberto Passera, PhD, Massimo Di Nicola, MD, Corrado Tarella, MD, Alessandro M. Gianni, MD

Blood (2010) 116 (21): 1289.

https://doi.org/10.1182/blood.V116.21.1289.1289

Published: 2010

Journal Articles

Clinical Activity and Safety of the Combined Therapy with the AKT Inhibitor Perifosine and the Multikinase Inhibitor Sorafenib In Heavily Pretreated Patients with Relapsed/Refractory Lymphomas: Preliminary Results of a Phase II Trial

Carmelo Carlo-Stella, MD, Anna Guidetti, MD, Simonetta Viviani, MD, Liliana Devizzi, MD, Paola Matteucci, MD, Alfonso Marchianò, MD, Rodolfo Lanocita, MD, Stefania Zambelli, MD, Roberto Sorasio, MD, Massimo Di Nicola, MD, Paolo Corradini, MD, Alessandro M. Gianni, MD

Blood (2010) 116 (21): 2861.

https://doi.org/10.1182/blood.V116.21.2861.2861

Published: 2010

Journal Articles

Preliminary Results of a Phase II Trial with the Multikinase Inhibitor Sorafenib in Heavily Pretreated Patients with Relapsed/Refractory Non-Hodgkin Lymphoma (NHL).

Anna Guidetti, MD, Carmelo Carlo-Stella, MD, Liliana Devizzi, MD, Paola Matteucci, MD, Alfonso Marchianò, MD, Rodolfo Lanocita, MD, Michele Magni, MD, Anna Dodero, MD, Corrado Tarella, MD, Massimo Di Nicola, MD, Paolo Corradini, MD, Alessandro M. Gianni, MD

Blood (2009) 114 (22): 1658.

https://doi.org/10.1182/blood.V114.22.1658.1658

Published: 2009

Journal Articles

Vaccination with autologous tumor-loaded dendritic cells induces clinical and immunologic responses in indolent B-cell lymphoma patients with relapsed and measurable disease: a pilot study

Massimo Di Nicola, Roberta Zappasodi, Carmelo Carlo-Stella, Roberta Mortarini, Serenella M. Pupa, Michele Magni, Liliana Devizzi, Paola Matteucci, Paola Baldassari, Fernando Ravagnani, Antonello Cabras, Andrea Anichini, Alessandro M. Gianni

Blood (2009) 113 (1): 18–27.

https://doi.org/10.1182/blood-2008-06-165654

Published: 2009

Includes: Supplemental data

Journal Articles

Long-Term Follow-up of Patients Affected by Relapsed Lymphomas Receiving Reduced-Intensity Conditioning (RIC) Regimen Followed by Allogeneic Stem Cell Transplantation (Allo-SCT): An Update of the Phase II Study of the Gruppo Italiano Trapianto Di Midollo Osseo (GITMO)

Blood (2008) 112 (11): 3303.

https://doi.org/10.1182/blood.V112.11.3303.3303

Published: 2008

Journal Articles

Monitoring of Post-Transplant Hematopoiesis in Patients Receiving High-Dose Yttrium-90-Ibritumomab Tiuxetan (Zevalin®) with Autograft: Lack of Detection of Remarkable Abnormalities.

Anna Guidetti, MD, Carmelo Carlo-Stella, MD, Alberto Rocci, MD, Liliana Devizzi, MD, Daniela Sia, PhD, Adele Testi, PhD, Michele Magni, MD, Massimo Di Nicola, MD, Paola Matteucci, MD, Alessandra Risso, PhD, Marco Ruella, MD, Corrado Tarella, MD, Alesandro M. Gianni, MD

Blood (2008) 112 (11): 2158.

https://doi.org/10.1182/blood.V112.11.2158.2158

Published: 2008

Journal Articles

High-Dose Myeloablative Zevalin Radioimmunotherapy with Tandem Stem-Cell Autografting Has Promising Activity, Minimal Toxicity and Full Feasibility in an Outpatient Setting.

Liliana Devizzi, MD, Ettore Seregni, MD, Anna Guidetti, MD, Chiara Forni, MD, Angela Coliva, MD, Michele Magni, MD, Massimo Di Nicola, MD, Carmelo Carlo-Stella, MD, Paola Matteucci, MD, Antonella De Pascale, MD, Claudia Erminero, MD, Marco Maccauro, MD, Carlo Chiesa, PhD, Emilio Bombardieri, MD, Pinuccia Valagussa, Alessandro M. Gianni, MD

Blood (2006) 108 (11): 3047.

https://doi.org/10.1182/blood.V108.11.3047.3047

Published: 2006

Journal Articles

High-Dose Myeloablative Zevalin Radioimmunotherapy with Tandem Stem-Cell Autografting Has Minimal Toxicity and Full Feasibility in an Outpatient Setting.

Liliana Devizzi, MD, Ettore Seregni, MD, Anna Guidetti, MD, Chiara Forni, MD, Angela Coliva, PhD, Michele Magni, MD, Massimo Di Nicola, MD, Carmelo Carlo-Stella, MD, Paola Matteucci, MD, Antonella De Pascale, MD, Claudia Erminero, MD, Marco Maccauro, MD, Carlo Chiesa, MD, Emilio Bombardieri, MD, Alessandro M. Gianni, MD

Blood (2005) 106 (11): 2737.

https://doi.org/10.1182/blood.V106.11.2737.2737

Published: 2005

Journal Articles

A Phase I Study of Immunization of Indolent Non Hodgkin’s Lymphoma Patients with Autologous Monocyte-Derived Dendritic Cells Loaded with Heat Shocked and Killed Autologous Tumor Cells.

Massimo Di Nicola, MD, Carmelo Carlo-Stella, MD, Maddalena Marchesi, MD, Gianluca Del Conte, MD, Liliana Devizzi, MD, Michele Magni, MD, Paola Matteucci, MD, Stefania Cresta, PhD, Roberta Mortarini, PhD, Andrea Anichini, PhD, Alessandro M. Gianni

Blood (2005) 106 (11): 2437.

https://doi.org/10.1182/blood.V106.11.2437.2437

Published: 2005

Journal Articles

Use of recombinant human growth hormone (rhGH) plus recombinant human granulocyte colony-stimulating factor (rhG-CSF) for the mobilization and collection of CD34 + cells in poor mobilizers

Carmelo Carlo-Stella, Massimo Di Nicola, Raffaella Milani, Anna Guidetti, Michele Magni, Marco Milanesi, Paolo Longoni, Paola Matteucci, Franca Formelli, Fernando Ravagnani, Paolo Corradini, Alessandro M. Gianni

Blood (2004) 103 (9): 3287–3295.

https://doi.org/10.1182/blood-2003-07-2428

Published: 2004

Journal Articles

Leukoencephalopathy and papovavirus infection after treatment with chemotherapy and anti-CD20 monoclonal antibody

Paola Matteucci, Michele Magni, Massimo Di Nicola, Carmelo Carlo-Stella, Caterina Uberti, Alessandro M. Gianni

Blood (2002) 100 (3): 1104–1105.

https://doi.org/10.1182/blood-2002-04-1271

Published: 2002

Journal Articles

Human bone marrow stromal cells suppress T-lymphocyte proliferation induced by cellular or nonspecific mitogenic stimuli

Massimo Di Nicola, Carmelo Carlo-Stella, Michele Magni, Marco Milanesi, Paolo D. Longoni, Paola Matteucci, Salvatore Grisanti, Alessandro M. Gianni

Blood (2002) 99 (10): 3838–3843.

https://doi.org/10.1182/blood.V99.10.3838

Published: 2002

Journal Articles

Successful in vivo purging of CD34-containing peripheral blood harvests in mantle cell and indolent lymphoma: evidence for a role of both chemotherapy and rituximab infusion

Michele Magni, Massimo Di Nicola, Liliana Devizzi, Paola Matteucci, Fabrizio Lombardi, Lorenza Gandola, Fernando Ravagnani, Roberto Giardini, Giuseppe Dastoli, Corrado Tarella, Alessandro Pileri, Gianni Bonadonna, Alessandro M. Gianni

Blood (2000) 96 (3): 864–869.

https://doi.org/10.1182/blood.V96.3.864

Published: 2000

NARROW

Rituximab Dose Adjusted EPOCH Improves Progression-Free Survival of Patients Affected By Diffuse Large Cell Lymphomas with Double Expression of MYC and BCL2 Proteins

TARC before ASCT Is Highly Predictive of Outcome in Patients with Relapsed or Refractory (R/R) Classical Hodgkin Lymphoma (cHL) after First-Line Therapy

Brentuximab Vedotin (BV) an Effective Treatment for Autologous (ASCT) and/or Allogeneic (alloSCT) Transplant naïve Patients with Relapsed/Refractory (R/R) Hodgkin Lymphoma (HL) : A retrospective Single-Institution Study

High Cure Rates of the Short-Term GITIL Chemotherapy Programme for Adult Patients with Burkitt Lymphoma

Rituximab Followed by Involved Fields Radiotherapy (IF-RT) in Stage I-II Follicular Lymphoma (FL): Long Term Results,

Safety, Tolerability and Activity of Ofatumumab, Bendamustine and Dexamethasone Combination As First-Line Treatment of Mantle-Cell Lymphoma in the Elderly: A Multicenter Study

The Risk of Secondary Myelodysplastic Syndrome/Acute Leukemia Following High-Dose Yttrium-90 Ibritumomab Tiuxetan Is Analogous to That Observed Following High-Dose Chemotherapy: a Matched-Pair Analysis In Non-Hodgkin Lymphoma Patients.

Clinical Activity and Safety of the Combined Therapy with the AKT Inhibitor Perifosine and the Multikinase Inhibitor Sorafenib In Heavily Pretreated Patients with Relapsed/Refractory Lymphomas: Preliminary Results of a Phase II Trial

Preliminary Results of a Phase II Trial with the Multikinase Inhibitor Sorafenib in Heavily Pretreated Patients with Relapsed/Refractory Non-Hodgkin Lymphoma (NHL).

Vaccination with autologous tumor-loaded dendritic cells induces clinical and immunologic responses in indolent B-cell lymphoma patients with relapsed and measurable disease: a pilot study

Long-Term Follow-up of Patients Affected by Relapsed Lymphomas Receiving Reduced-Intensity Conditioning (RIC) Regimen Followed by Allogeneic Stem Cell Transplantation (Allo-SCT): An Update of the Phase II Study of the Gruppo Italiano Trapianto Di Midollo Osseo (GITMO)

Monitoring of Post-Transplant Hematopoiesis in Patients Receiving High-Dose Yttrium-90-Ibritumomab Tiuxetan (Zevalin®) with Autograft: Lack of Detection of Remarkable Abnormalities.

High-Dose Myeloablative Zevalin Radioimmunotherapy with Tandem Stem-Cell Autografting Has Promising Activity, Minimal Toxicity and Full Feasibility in an Outpatient Setting.

High-Dose Myeloablative Zevalin Radioimmunotherapy with Tandem Stem-Cell Autografting Has Minimal Toxicity and Full Feasibility in an Outpatient Setting.

A Phase I Study of Immunization of Indolent Non Hodgkin’s Lymphoma Patients with Autologous Monocyte-Derived Dendritic Cells Loaded with Heat Shocked and Killed Autologous Tumor Cells.

Use of recombinant human growth hormone (rhGH) plus recombinant human granulocyte colony-stimulating factor (rhG-CSF) for the mobilization and collection of CD34 + cells in poor mobilizers

Leukoencephalopathy and papovavirus infection after treatment with chemotherapy and anti-CD20 monoclonal antibody

Human bone marrow stromal cells suppress T-lymphocyte proliferation induced by cellular or nonspecific mitogenic stimuli

Successful in vivo purging of CD34-containing peripheral blood harvests in mantle cell and indolent lymphoma: evidence for a role of both chemotherapy and rituximab infusion

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only